

Emily C. Zabor

Curriculum Vitae

9500 Euclid Ave. CA-60
Cleveland, OH 44195
☎ 216-445-9419
✉ zabore2@ccf.org
🌐 emilyzabor.com

Education

- 2013–2019 **Doctor of Public Health**, *Columbia University*, New York, NY, Biostatistics.
Dissertation topic: Statistical methods for the study of etiologic heterogeneity
Advisors: Dr. Colin Begg and Dr. Shuang Wang
- 2008–2010 **Master of Science**, *The University of Minnesota*, Minneapolis, MN, Biostatistics.
- 1999–2003 **Bachelor of Arts**, *Grinnell College*, Grinnell, IA, Anthropology.

Professional positions

- 2019–Present **Assistant Staff**, CLEVELAND CLINIC, Cleveland, OH.
Department of Quantitative Health Sciences & Taussig Cancer Institute
- 2018–2019 **Senior Research Biostatistician**, MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY.
Department of Epidemiology & Biostatistics
- 2015–2017 **Research Biostatistician II**, MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY.
Department of Epidemiology & Biostatistics
- 2012–2015 **Research Biostatistician I**, MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY.
Department of Epidemiology & Biostatistics
- 2010–2012 **Assistant Research Biostatistician**, MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY.
Department of Epidemiology & Biostatistics

Academic positions

- 2020–Present **Assistant Professor of Medicine**, CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE AT CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH.
Department of Medicine
- 2016–2017 **Adjunct Professor**, HUNTER COLLEGE, New York, NY.
Fundamentals of Biostatistics

Other employment

- Fall 2017 **Teaching Assistant**, COLUMBIA UNIVERSITY, New York, NY.
Data Science I
- 2009 **Summer Intern in Biomedical Research**, NATIONAL INSTITUTES OF HEALTH, Bethesda, MD.
Eunice Kennedy Shriver National Institute for Child Health & Human Development

- 2009–2010 **Research Assistant**, THE UNIVERSITY OF MINNESOTA, Minneapolis, MN.
Coordinating Centers for Biometric Research
- 2008–2010 **Teaching Assistant**, THE UNIVERSITY OF MINNESOTA, Minneapolis, MN.
Introduction to Biostatistics
Advanced Topics in Clinical Trials
- 2008–2009 **Research Assistant**, THE UNIVERSITY OF MINNESOTA, Minneapolis, MN.
Division of Health Policy and Management
- 2006–2008 **Account Coordinator**, US BANK, Minneapolis, MN.
Corporate Payment Systems
- 2003–2006 **Volunteer**, US PEACE CORPS, Ghana, West Africa.
Natural Resources for Livelihood Sustainability Program

Methodologic publications

1. **Zabor, E. C.**, Kaizer, A. M., Garrett-Mayer, E. & Hobbs, B. P. (Under review). Optimal sequential predictive probability designs for early phase oncology expansion cohorts.
2. **Zabor, E. C.**, Kane, M. J., Roychoudhury, S., Nie, L., & Hobbs, B. P. (Under review). Bayesian Basket Trial Design with False Discovery Rate Control.
3. Eaton, A. A. and **Zabor, E. C.** (Under review). Analysis of composite endpoints with component-wise censoring in the presence of differential visit schedules.
4. Kaizer, A. M., **Zabor, E. C.**, Nie, L. & Hobbs, B. P. (Under review). Bayesian and Frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets.
5. **Zabor, E. C.**, Reddy, C. A., Tendulkar, R. D., & Patil, S. (2021). Logistic Regression in Clinical Studies. *Int J Radiat Oncol Biol Phys*. doi:10.1016/j.ijrobp.2021.08.007
6. **Zabor, E. C.**, Seshan, V. E., Wang, S., & Begg, C. B. (2021). Validity of a method for identifying disease subtypes that are etiologically heterogeneous. *Stat Methods Med Res*, 30(9), 2045-2056. doi:10.1177/09622802211032704
7. **Zabor, E. C.**, Kaizer, A. M., & Hobbs, B. P. (2020). Randomized Controlled Trials. *Chest*, 158(1s), S79-s87. doi:10.1016/j.chest.2020.03.013
8. **Zabor, E. C.** (2019). riskclustr: Functions to Study Etiologic Heterogeneity. *Journal of Open Source Software*, 4(35), 1269. doi:10.21105/joss.01269
9. **Zabor, E. C.**, Coit, D., Gershenwald, J. E., McMasters, K. M., Michaelson, J. S., Stromberg, A. J., & Panageas, K. S. (2018). Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors. *Ann Surg Oncol*, 25(8), 2172-2177. doi:10.1245/s10434-018-6370-4
10. **Zabor, E. C.**, & Begg, C. B. (2017). A comparison of statistical methods for the study of etiologic heterogeneity. *Stat Med*, 36(25), 4050-4060. doi:10.1002/sim.7405
11. Mauguén, A., **Zabor, E. C.**, Thomas, N. E., Berwick, M., Seshan, V. E., & Begg, C. B. (2017). Defining Cancer Subtypes With Distinctive Etiologic Profiles: An Application to the Epidemiology of Melanoma. *J Am Stat Assoc*, 112(517), 54-63. doi:10.1080/01621459.2016.1191499
12. **Zabor, E. C.**, Heller, G., Schwartz, L. H., Chapman, P. B. (2016). Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib. *Clin Cancer Res*, 22(6), 1341-1347. doi:10.1158/1078-0432.Ccr-15-1441
13. Begg, C. B., Orlow, I., **Zabor, E. C.**, Arora, A., Sharma, A., Seshan, V. E., & Bernstein, J. L. (2015). Identifying Etiologically Distinct Sub-Types of Cancer: A Demonstration Project

- Involving Breast Cancer. *Cancer Med*, 4(9), 1432-1439. doi:10.1002/cam4.456
14. Begg, C. B., Seshan, V. E., **Zabor, E. C.**, Furberg, H., Arora, A., Shen, R., ... Hsieh, J. J. (2014). Genomic investigation of etiologic heterogeneity: methodologic challenges. *BMC Med Res Methodol*, 14, 138. doi:10.1186/1471-2288-14-138
 15. **Zabor, E. C.**, Gonen, M., Chapman, P. B., Panageas, K. S. (2013). Dynamic prognostication using conditional survival estimates. *Cancer*, 119(20), 3589-3592. doi:10.1002/cncr.28273
 16. Begg, C. B., **Zabor, E. C.**, Bernstein, J. L., Bernstein, L., Press, M. F., Seshan, V. E. (2013). A conceptual and methodological framework for investigating etiologic heterogeneity. *Stat Med*, 32(29), 5039-5052. doi:10.1002/sim.5902
 17. Begg, C. B., **Zabor, E. C.** (2012). Detecting and exploiting etiologic heterogeneity in epidemiologic studies. *Am J Epidemiol*, 176(6), 512-518. doi:10.1093/aje/kws128

Collaborative publications

1. **Zabor, E. C.**, Radivoyevitch, T., Singh, A. D., Kilic, E., de Klein, J., Kalirai, H., & Coupland, S. E. (2021). Conditional Survival in Uveal Melanoma. *Ophthalmol Retina*, 5(6), 536-542. doi:10.1016/j.oret.2020.09.015
2. Tadros, A. B., Sevilimedu, V., Giri, D. D., **Zabor, E. C.**, Morrow, M., & Plitas, G. (2021). Survival Outcomes for Metaplastic Breast Cancer Differ by Histologic Subtype. *Ann Surg Oncol*, 28(8), 4245-4253. doi:10.1245/s10434-020-09430-5
3. Singh, A. D., **Zabor, E. C.**, & Radivoyevitch, T. (2021). Estimating Cured Fractions of Uveal Melanoma. *JAMA Ophthalmol*, 139(2), 174-181. doi:10.1001/jamaophthalmol.2020.5720
4. Radivoyevitch, T., **Zabor, E. C.**, & Singh, A. D. (2021). Uveal melanoma: Long-term survival. *PLoS One*, 16(5), e0250939. doi:10.1371/journal.pone.0250939
5. Pawloski, K. R., Tadros, A. B., Sevilimedu, V., Newman, A., Gentile, L., **Zabor, E. C.**, Morrow, M., Van Zee, K. J., & Kirstein, L. J. (2021). Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy. *Breast Cancer Res Treat*, 186(3), 617-624. doi:10.1007/s10549-021-06129-3
6. Palacios, D. A., **Zabor, E. C.**, Munoz-Lopez, C., Roversi, G., Mahmood, F., Abramczyk, E., Kelly, M., Wilson, B., Abouassaly, R., & Campbell, S. C. (2021). Does Reduced Renal Function Predispose to Cancer-specific Mortality from Renal Cell Carcinoma? *Eur Urol*, 79(6), 774-780. doi:10.1016/j.eururo.2021.02.035
7. Elimimian, E. B., Elson, L., Li, H., Liang, H., Bilani, N., **Zabor, E. C.**, Statler, A., & Nahleh, Z. (2021). Male Breast Cancer: A Comparative Analysis from the National Cancer Database. *World J Mens Health*, 39(3), 506-515. doi:10.5534/wjmh.200164
8. Walsh, S. M., **Zabor, E. C.**, Flynn, J., Stempel, M., Morrow, M., & Gemignani, M. L. (2020). Breast cancer in young black women. *Br J Surg*, 107(6), 677-686. doi:10.1002/bjs.11401
9. Vickers, A. J., Assel, M. J., Sjoberg, D. D., Qin, R., Zhao, Z., Koyama, T., Botchway A., Wang X., Huo D., Kattan M., **Zabor E.C.**, & Harrell, F. (2020). Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. *BJU Int*, 126(1), 14-25. doi:10.1111/bju.15102
10. Vickers, A. J., Assel, M. J., Sjoberg, D. D., Qin, R., Zhao, Z., Koyama, T., Botchway A., Wang X., Huo D., Kattan M., **Zabor E.C.**, & Harrell, F. (2020). Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. *Eur Urol*, 78(1), 97-109. doi:10.1016/j.eururo.2020.04.048
11. Vickers, A. J., Assel, M. J., Sjoberg, D. D., Qin, R., Zhao, Z., Koyama, T., Botchway A., Wang X., Huo D., Kattan M., **Zabor E.C.**, & Harrell, F. (2020). Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. *Urology*, 142, 1-13. doi:10.1016/j.urology.2020.05.002
12. Vickers, A. J., Assel, M. J., Sjoberg, D. D., Qin, R., Zhao, Z., Koyama, T., Botchway

- A., Wang X., Huo D., Kattan M., **Zabor E.C.**, & Harrell, F. (2020). Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. *J Urol*, 204(1), 121-133. doi:10.1097/ju.0000000000001096
13. Valero, M. G., Moo, T. A., Muhsen, S., Zabor, E. C., Stempel, M., Pusic, A., Gemignani M.L., Morrow M., & Sacchini, V. (2020). Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer. *Br J Surg*. doi:10.1002/bjs.11616
 14. Valero, M. G., Muhsen, S., Moo, T. A., **Zabor, E. C.**, Stempel, M., Pusic, A., Gemignani M.L., Morrow M., & Sacchini, V. S. (2020). Increase in Utilization of Nipple-Sparing Mastectomy for Breast Cancer: Indications, Complications, and Oncologic Outcomes. *Ann Surg Oncol*, 27(2), 344-351. doi:10.1245/s10434-019-07948-x
 15. Valero, M. G., **Zabor, E. C.**, Park, A., Gilbert, E., Newman, A., King, T. A., & Pilewskie, M. L. (2020). The Tyrer-Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS. *Ann Surg Oncol*, 27(3), 736-740. . doi:10.1245/s10434-019-07814-w
 16. Tadros, A. B., Moo, T. A., Stempel, M., **Zabor, E. C.**, Khan, A. J., & Morrow, M. (2020). Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy. *Breast Cancer Res Treat*, 180(1), 197-205. doi:10.1007/s10549-019-05520-5
 17. Tadros, A. B., Moo, T. A., **Zabor, E. C.**, Gillespie, E. F., Khan, A., McCormick, B., Cahlon, O., Powell, S. N., Allen, R., Jr., Morrow, M., & Braunstein, L. Z. (2020). Feasibility of Breast-Conservation Therapy and Hypofractionated Radiation in the Setting of Prior Breast Augmentation. *Pract Radiat Oncol*, 10(5), e357-e362. doi:10.1016/j.prro.2020.01.003
 18. Raghunathan, N. J., **Zabor, E. C.**, Anderson, N., Oeffinger, K., Tonorezos, E. S., & Korenstein, D. (2020). Communicating cardiovascular risk to high-risk cancer survivors: a mixed-methods pilot study of a statin risk communication tool. *J Cancer Surviv*, 14(4), 417-423. doi:10.1007/s11764-020-00860-4
 19. Niehoff, N. M., **Zabor, E. C.**, Satagopan, J., Widell, A., O'Brien, T. R., Zhang, M., Rothman, N., Grimsrud, T. K., Van Den Eeden, S. K., & Engel, L. S. (2020). Pre-diagnostic serum polychlorinated biphenyl concentrations and primary liver cancer: A case-control study nested within two prospective cohorts. *Environ Res*, 187, 109690. doi:10.1016/j.envres.2020.109690
 20. Minami, C. A., **Zabor, E. C.**, Gilbert, E., Newman, A., Park, A., Jochelson, M. S., King, T. A., & (2020). Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ? *Ann Surg Oncol*, 27(6), 1844-1851. doi:10.1245/s10434-019-08126-9
 21. Iyer, G., Tully, C. M., **Zabor, E. C.**, Bochner, B. H., Dalbagni, G., Herr, H. W., Donat, S. M., Russo, P., Ostrovnya, I., Regazzi, A. M., Milowsky, M. I., Rosenberg, J. E., & Bajorin, D. F. (2020). Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. *Clin Genitourin Cancer*. doi:10.1016/j.clgc.2020.02.014
 22. Crown, A., Muhsen, S., **Zabor, E. C.**, Sevilimedu, V., Kelvin, J., Goldfarb, S. B., & Gemignani, M. L. (2020). Does Use of Neoadjuvant Chemotherapy Affect the Decision to Pursue Fertility Preservation Options in Young Women with Breast Cancer? *Ann Surg Oncol*. doi:10.1245/s10434-020-08883-y
 23. Christian, N., **Zabor, E. C.**, Cassidy, M., Flynn, J., Morrow, M., & Gemignani, M. L. (2020). Contralateral Prophylactic Mastectomy Use After Neoadjuvant Chemotherapy. *Ann Surg Oncol*, 27(3), 743-749. doi:10.1245/s10434-019-08038-8
 24. Brierley, C. K., **Zabor, E. C.**, Komrokji, R. S., DeZern, A. E., Roboz, G. J., Brunner, A. M., Stone, R. M., Sekeres, M. A., & Steensma, D. P. (2020). Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes.

- Cancer*. doi:10.1002/cncr.33105
25. Bilani, N., **Zabor, E. C.**, Elson, L., Elimimian, E. B., & Nahleh, Z. (2020). Breast Cancer in the United States: A Cross-Sectional Overview. *J Cancer Epidemiol*, 2020, 6387378. doi:10.1155/2020/6387378
 26. Walsh, S. M., Brennan, S. B., **Zabor, E. C.**, Rosenberger, L. H., Stempel, M., Lebron-Zapata, L., & Gemignani, M. L. (2019). Does Breast Density Increase the Risk of Re-excision for Women with Breast Cancer Having Breast-Conservation Therapy? *Ann Surg Oncol*, 26(13), 4246-4253. doi:10.1245/s10434-019-07647-7
 27. Walsh, S. M., **Zabor, E. C.**, Stempel, M., Morrow, M., & Gemignani, M. L. (2019). Does race predict survival for women with invasive breast cancer? *Cancer*, 125(18), 3139-3146. doi:10.1002/cncr.32296
 28. Van Zee, K. J., **Zabor, E. C.**, Di Donato, R., Harmon, B., Fox, J., Morrow, M., Cody, H. S., 3rd, & Fineberg, S. A. (2019). Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Versus Refined Oncotype DX Breast DCIS Score. *Ann Surg Oncol*, 26(10), 3282-3288. doi:10.1245/s10434-019-07537-y
 29. Spanheimer, P. M., Murray, M. P., **Zabor, E. C.**, Stempel, M., Morrow, M., Van Zee, K. J., & Barrio, A. V. (2019). Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast. *Ann Surg Oncol*, 26(7), 2136-2143. doi:10.1245/s10434-019-07210-4
 30. Pilewskie, M., **Zabor, E. C.**, Gilbert, E., Stempel, M., Petruolo, O., Mangino, D., Robson, M., & Jochelson, M. S. (2019). Differences between screen-detected and interval breast cancers among BRCA mutation carriers. *Breast Cancer Res Treat*, 175(1), 141-148. doi:10.1007/s10549-018-05123-6
 31. Pietzak, E. J., **Zabor, E. C.**, Bagrodia, A., Armenia, J., Hu, W., Zehir, A., Funt, S., Audenet, F., Barron, D., Maamouri, N., Li, Q., Teo, M. Y., Arcila, M. E., Berger, M. F., Schultz, N., Dalbagni, G., Herr, H. W., Bajorin, D. F., Rosenberg, J. E., Al-Ahmadie, H., Bochner, B. H., Solit, D. B., & Iyer, G. (2019). Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. *Eur Urol*, 75(2), 231-239. doi:10.1016/j.eururo.2018.09.002
 32. Moo, T. A., Jochelson, M. S., Zabor, E. C., Stempel, M., Raiss, M., Mamtani, A., Tadros, A. B., El-Tamer, M., & Morrow, M. (2019). Is Clinical Exam of the Axilla Sufficient to Select Node-Positive Patients Who Downstage After NAC for SLNB? A Comparison of the Accuracy of Clinical Exam Versus MRI. *Ann Surg Oncol*, 26(13), 4238-4243. doi:10.1245/s10434-019-07867-x
 33. Miller, M. E., Muhsen, S., **Zabor, E. C.**, Flynn, J., Olcese, C., Giri, D., Van Zee, K. J., & Pilewskie, M. (2019). Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ. *Ann Surg Oncol*, 26(13), 4317-4325. doi:10.1245/s10434-019-07796-9
 34. Mamtani, A., **Zabor, E. C.**, Stempel, M., & Morrow, M. (2019). Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers. *Ann Surg Oncol*, 26(10), 3269-3274. doi:10.1245/s10434-019-07536-z
 35. Mamtani, A., **Zabor, E. C.**, Rosenberger, L. H., Stempel, M., Gemignani, M. L., & Morrow, M. (2019). Was Reexcision Less Frequent for Patients with Lobular Breast Cancer After Publication of the SSO-ASTRO Margin Guidelines? *Ann Surg Oncol*, 26(12), 3856-3862. doi:10.1245/s10434-019-07751-8
 36. Mamtani, A., Nakhli, F., Downs-Canner, S., **Zabor, E. C.**, Morrow, M., King, T. A., & Van Zee, K. J. (2019). Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion. *Ann Surg Oncol*, 26(13), 4264-4271. doi:10.1245/s10434-019-07693-1

37. Grabenstetter, A., Moo, T. A., Hajiyeva, S., Schuffler, P. J., Khattar, P., Friedlander, M. A., McCormack, M. A., Raiss, M., **Zabor, E. C.**, Barrio, A., Morrow, M., & Edelweiss, M. (2019). Accuracy of Intraoperative Frozen Section of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy for Breast Carcinoma. *Am J Surg Pathol*, 43(10), 1377-1383. doi:10.1097/pas.0000000000001311
38. Flanagan, M. R., **Zabor, E. C.**, Stempel, M., Mangino, D. A., Morrow, M., & Pilewskie, M. L. (2019). Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor. *Ann Surg Oncol*, 26(7), 2127-2135. doi:10.1245/s10434-019-07236-8
39. Flanagan, M. R., **Zabor, E. C.**, Romanoff, A., Fuzesi, S., Stempel, M., Mehrara, B. J., Morrow, M., Pusic, A. L., & Gemignani, M. L. (2019). A Comparison of Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Implant Breast Reconstruction. *Ann Surg Oncol*, 26(10), 3133-3140. doi:10.1245/s10434-019-07548-9
40. Engel, L. S., **Zabor, E. C.**, Satagopan, J., Widell, A., Rothman, N., O'Brien, T. R., Zhang, M., Van Den Eeden, S. K., & Grimsrud, T. K. (2019). Prediagnostic serum organochlorine insecticide concentrations and primary liver cancer: A case-control study nested within two prospective cohorts. *Int J Cancer*, 145(9), 2360-2371. doi:10.1002/ijc.32175
41. Downs-Canner, S., **Zabor, E. C.**, Wind, T., Cobovic, A., McCormick, B., Morrow, M., & Heerdt, A. (2019). Radiation Therapy After Breast-Conserving Surgery in Women 70 Years of Age and Older: How Wisely Do We Choose? *Ann Surg Oncol*, 26(4), 969-975. doi:10.1245/s10434-018-07151-4
42. Casuscelli, J., Becerra, M. F., Manley, B. J., **Zabor, E. C.**, Reznik, E., Redzematovic, A., Arcila, M. E., Tennenbaum, D. M., Ghanaat, M., Kashan, M., Stief, C. G., Carlo, M., Voss, M. H., Feldman, D. R., Motzer, R. J., Chen, Y., Reuter, V. E., Coleman, J. A., Russo, P., Hsieh, J. J., & Hakimi, A. A. (2019). Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. *Eur Urol Focus*, 5(4), 642-649. doi:10.1016/j.euf.2017.09.008
43. Benefield, H. C., **Zabor, E. C.**, Shan, Y., Allott, E. H., Begg, C. B., & Troester, M. A. (2019). Evidence for Etiologic Subtypes of Breast Cancer in the Carolina Breast Cancer Study. *Cancer Epidemiol Biomarkers Prev*, 28(11), 1784-1791. doi:10.1158/1055-9965.Epi-19-0365
44. Baker, J. L., Muhsen, S., **Zabor, E. C.**, Stempel, M., & Gemignani, M. L. (2019). Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed? *Ann Surg Oncol*, 26(2), 336-342. doi:10.1245/s10434-018-7004-6
45. Assel, M., Sjoberg, D., Elders, A., Wang, X., Huo, D., Botchway, A., Delfino, K., Fan, Y., Zhao, Z., Koyama, T., Hollenbeck, B., Qin, R., Zahnd, W., **Zabor, E. C.**, Kattan, M. W., & Vickers, A. J. (2019). Guidelines for Reporting of Statistics for Clinical Research in Urology. *J Urol*, 201(3), 595-604. doi:10.1097/ju.0000000000000001
46. Assel, M., Sjoberg, D., Elders, A., Wang, X., Huo, D., Botchway, A., Delfino, K., Fan, Y., Zhao, Z., Koyama, T., Hollenbeck, B., Qin, R., Zahnd, W., **Zabor, E. C.**, Kattan, M. W., & Vickers, A. J. (2019). Guidelines for Reporting of Statistics for Clinical Research in Urology. *Eur Urol*, 75(3), 358-367. doi:10.1016/j.eururo.2018.12.014
47. Assel, M., Sjoberg, D., Elders, A., Wang, X., Huo, D., Botchway, A., Delfino, K., Fan, Y., Zhao, Z., Koyama, T., Hollenbeck, B., Qin, R., Zahnd, W., **Zabor, E. C.**, Kattan, M. W., & Vickers, A. J. (2019). Guidelines for reporting of statistics for clinical research in urology. *BJU Int*, 123(3), 401-410. doi:10.1111/bju.14640
48. **Zabor, E. C.**, Furberg, H., Lee, B., Campbell, S., Lane, B. R., Thompson, R. H., Antonio, E. C., Noyes, S. L., Zaid, H., Jaimes, E. A., & Russo, P. (2018). Long-Term Renal Function Recovery following Radical Nephrectomy for Kidney Cancer: Results from a Multicenter Confirmatory Study. *J Urol*, 199(4), 921-926.
49. Winer, A. G., **Zabor, E. C.**, Vacchio, M. J., Hakimi, A. A., Russo, P., Coleman, J. A., &

- Jaimes, E. A. (2018). The Effect of Patient and Surgical Characteristics on Renal Function After Partial Nephrectomy. *Clin Genitourin Cancer*, 16(3), 191-196.
50. Silk, M. T., Mikkilineni, N., Silk, T. C., **Zabor, E. C.**, Ostrovnaya, I., Hakimi, A. A., Hsieh, J. J., Ziv, E., Rekhtman, N., Solomon, S. B., & Durack, J. C. (2018). Prospective Evaluation of Unprocessed Core Needle Biopsy DNA and RNA Yield from Lung, Liver, and Kidney Tumors: Implications for Cancer Genomics. *Anal Cell Pathol (Amst)*, 2018, 2898962.
 51. Scott, J. M., **Zabor, E. C.**, Schwitzer, E., Koelwyn, G. J., Adams, S. C., Nilsen, T. S., Moskowitz, C. S., Matsoukas, K., Iyengar, N. M., Dang, C. T., & Jones, L. W. (2018). Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis. *J Clin Oncol*, 36(22), 2297-2305.
 52. Romanoff, A., **Zabor, E. C.**, Stempel, M., Sacchini, V., Pusic, A., & Morrow, M. (2018). A Comparison of Patient-Reported Outcomes After Nipple-Sparing Mastectomy and Conventional Mastectomy with Reconstruction. *Ann Surg Oncol*, 25(10), 2909-2916.
 53. Romanoff, A., **Zabor, E. C.**, Petruolo, O., Stempel, M., El-Tamer, M., Morrow, M., & Barrio, A. V. (2018). Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers? *Cancer*, 124(22), 4314-4321.
 54. Moo, T. A., Edelweiss, M., Hajiyeva, S., Stempel, M., Raiss, M., **Zabor, E. C.**, Barrio, A., & Morrow, M. (2018). Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? *Ann Surg Oncol*, 25(6), 1488-1494.
 55. Lee, B. H., **Zabor, E. C.**, Tennenbaum, D., Furberg, H., Benfante, N., Coleman, J. A., Jaimes, E. A., & Russo, P. (2018). Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol*, 36(2), 257-263.
 56. Francis, J. H., Levin, A. M., **Zabor, E. C.**, Gobin, Y. P., & Abramson, D. H. (2018). Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival. *PLoS One*, 13(5), e0197081.
 57. Cronin, P. A., Romanoff, A., **Zabor, E. C.**, Stempel, M., Eaton, A., Smyth, L. M., Ho, A. Y., Morrow, M., El-Tamer, M., & Gemignani, M. L. (2018). Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers. *Ann Surg Oncol*, 25(13), 3858-3866.
 58. Cassidy, M. R., **Zabor, E. C.**, Stempel, M., Mehrara, B., & Gemignani, M. L. (2018). Does response to neo-adjuvant chemotherapy impact breast reconstruction? *Breast J*, 24(4), 567-573.
 59. Weber, J. J., Jochelson, M. S., Eaton, A., **Zabor, E. C.**, Barrio, A. V., Gemignani, M. L., Pilewskie, M., Van Zee, K. J., Morrow, M., & El-Tamer, M. (2017). MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer: MRI and Pathologic Complete Response. *J Am Coll Surg*, 225(6), 740-746.
 60. Teo, M. Y., Bambury, R. M., **Zabor, E. C.**, Jordan, E., Al-Ahmadie, H., Boyd, M. E., Bouvier, N., Mullane, S. A., Cha, E. K., Roper, N., Ostrovnaya, I., Hyman, D. M., Bochner, B. H., Arcila, M. E., Solit, D. B., Berger, M. F., Bajorin, D. F., Bellmunt, J., Iyer, G., & Rosenberg, J. E. (2017). DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. *Clin Cancer Res*, 23(14), 3610-3618.
 61. Schwitzer, E., Orlow, I., **Zabor, E. C.**, Begg, C. B., Berwick, M., Thomas, N. E., Kanetsky, P. A., & Jones, L. W. (2017). No association between prediagnosis exercise and survival in patients with high-risk primary melanoma: A population-based study. *Pigment Cell Melanoma Res*, 30(4), 424-427.
 62. Salz, T., **Zabor, E. C.**, de Nully Brown, P., Dalton, S. O., Raghunathan, N. J., Matasar, M. J., Steingart, R., Vickers, A. J., Svenssen Munksgaard, P., Oeffinger, K. C., & Johansen, C.

- (2017). Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. *J Clin Oncol*, 35(34), 3837-3843.
63. Pilewskie, M., **Zabor, E. C.**, Mamtani, A., Barrio, A. V., Stempel, M., & Morrow, M. (2017). The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype. *Ann Surg Oncol*, 24(12), 3527-3533.
 64. McCartan, D. P., **Zabor, E. C.**, Morrow, M., Van Zee, K. J., & El-Tamer, M. B. (2017). Oncologic Outcomes After Treatment for MRI Occult Breast Cancer (pT0N+). *Ann Surg Oncol*, 24(11), 3141-3147.
 65. Manley, B. J., **Zabor, E. C.**, Casuscelli, J., Tennenbaum, D. M., Redzematovic, A., Becerra, M. F., Benfante, N., Sato, Y., Morikawa, T., Kume, H., Fukayama, M., Homma, Y., Ogawa, S., Arcila, M. E., Voss, M. H., Feldman, D. R., Coleman, J. A., Reuter, V. E., Motzer, R. J., Russo, P., Hsieh, J. J., & Hakimi, A. A. (2017). Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. *Eur Urol Focus*, 3(4-5), 421-427.
 66. Gilbert, E., **Zabor, E. C.**, Stempel, M., Mangino, D., Heerdt, A., & Pilewskie, M. (2017). Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance. *Ann Surg Oncol*, 24(10), 3048-3054.
 67. Gentile, L. F., Plitas, G., **Zabor, E. C.**, Stempel, M., Morrow, M., & Barrio, A. V. (2017). Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer. *Ann Surg Oncol*, 24(13), 3896-3902.
 68. Francis, J. H., Brodie, S. E., Marr, B., **Zabor, E. C.**, Mondesire-Crump, I., & Abramson, D. H. (2017). Efficacy and Toxicity of Intravitreal Chemotherapy for Retinoblastoma: Four-Year Experience. *Ophthalmology*, 124(4), 488-495.
 69. Cho, G. Y., Gennaro, L., Sutton, E. J., **Zabor, E. C.**, Zhang, Z., Giri, D., Moy, L., Sodickson, D. K., Morris, E. A., Sigmund, E. E., & Thakur, S. B. (2017). Intravoxel incoherent motion (IVIM) histogram biomarkers for prediction of neoadjuvant treatment response in breast cancer patients. *Eur J Radiol Open*, 4, 101-107.
 70. Casuscelli, J., Weinhold, N., Gundem, G., Wang, L., **Zabor, E. C.**, Drill, E., Wang, P. I., Nanjangud, G. J., Redzematovic, A., Nargund, A. M., Manley, B. J., Arcila, M. E., Donin, N. M., Cheville, J. C., Thompson, R. H., Pantuck, A. J., Russo, P., Cheng, E. H., Lee, W., Tickoo, S. K., Ostrovnya, I., Creighton, C. J., Papaemmanuil, E., Seshan, V. E., Hakimi, A. A., & Hsieh, J. J. (2017). Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. *JCI Insight*, 2(12).
 71. Campbell, P. T., Rebbeck, T. R., Nishihara, R., Beck, A. H., Begg, C. B., Bogdanov, A. A., Cao, Y., Coleman, H. G., Freeman, G. J., Heng, Y. J., Huttenhower, C., Irizarry, R. A., Kip, N. S., Michor, F., Nevo, D., Peters, U., Phipps, A. I., Poole, E. M., Qian, Z. R., Quackenbush, J., Robins, H., Rogan, P. K., Slattey, M. L., Smith-Warner, S. A., Song, M., VanderWeele, T. J., Xia, D., Zabor, E. C., Zhang, X., Wang, M., & Ogino, S. (2017). Proceedings of the third international molecular pathological epidemiology (MPE) meeting. *Cancer Causes Control*, 28(2), 167-176.
 72. Boursiquot, B. C., **Zabor, E. C.**, Glezerman, I. G., & Jaimes, E. A. (2017). Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal Function. *Hypertension*.
 73. Begg, C. B., Rice, M. S., **Zabor, E. C.**, & Tworoger, S. S. (2017). Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries. *Br J Cancer*, 116(8), 1088-1091.

74. Alanee, S. R., Shah, S., **Zabor, E. C.**, Vijai, J., Ostrovnaya, I., Garcia-Grossman, I. R., Pendse, D. V., Littman, J., Regazzi, A. M., Offit, K., & Bajorin, D. F. (2017). Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder. *Int J Clin Pharmacol Ther*, 55 (2017)(3), 203-209.
75. **Zabor, E. C.**, Furberg, H., Mashni, J., Lee, B., Jaimes, E. A., Russo, P. (2016). Factors Associated with Recovery of Renal Function following Radical Nephrectomy for Kidney Neoplasms. *Clin J Am Soc Nephrol*, 11(1), 101-107.
76. Yu, A. F., Raikhelkar, J., **Zabor, E. C.**, Tonorezos, E. S., Moskowitz, C. S., Adsuar, R., Mara, E., Huie, K., Oeffinger, K. C., Steingart, R. M., & Liu, J. E. (2016). Two-Dimensional Speckle Tracking Echocardiography Detects Subclinical Left Ventricular Systolic Dysfunction among Adult Survivors of Childhood, Adolescent, and Young Adult Cancer. *Biomed Res Int*, 2016, 9363951.
77. Tully, C. M., Apolo, A. B., **Zabor, E. C.**, Regazzi, A. M., Ostrovnaya, I., Furberg, H. F., Rosenberg, J. E., & Bajorin, D. F. (2016). The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. *Cancer*, 122(5), 712-721.
78. Thong, A. E., Petruzella, S., Orlow, I., **Zabor, E. C.**, Ehdaie, B., Ostroff, J. S., Bochner, B. H., & Furberg Barnes, H. (2016). Accuracy of Self-reported Smoking Exposure Among Bladder Cancer Patients Undergoing Surveillance at a Tertiary Referral Center. *Eur Urol Focus*, 2(4), 441-444.
79. Spitzer, B., Perales, M. A., Kernan, N. A., Prockop, S. E., **Zabor, E. C.**, Webb, N., Castro-Malaspina, H., Papadopoulos, E. B., Young, J. W., Scaradavou, A., Kobos, R., Giralt, S. A., O'Reilly, R. J., & Boulad, F. (2016). Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cyto-reduction with Clofarabine, Melphalan, and Thiotepa. *Biol Blood Marrow Transplant*, 22(8), 1449-1454.
80. Murray, K. S., **Zabor, E. C.**, Spaliviero, M., Russo, P., Bazzi, W. M., Musser, J. E., Ari Hakimi, A., Bernstein, M. L., Dalbagni, G., Coleman, J. A., & Furberg, H. (2016). Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution. *World J Urol*, 34(12), 1667-1672.
81. Hay, J. L., **Zabor, E. C.**, Kumar, J., Brennessel, D., Kemeny, M. M., Lubetkin, E. I. (2016). Cancer beliefs and patient activation in a diverse, multilingual primary care sample. *Psychooncology*, 25(9), 1071-1078.
82. Desai, N. B., Scott, S. N., **Zabor, E. C.**, Cha, E. K., Hreiki, J., Sfakianos, J. P., Ramirez, R., Bagrodia, A., Rosenberg, J. E., Bajorin, D. F., Berger, M. F., Bochner, B. H., Zelefsky, M. J., Kollmeier, M. A., Ostrovnaya, I., Al-Ahmadie, H. A., Solit, D. B., & Iyer, G. (2016). Genomic characterization of response to chemoradiation in urothelial bladder cancer. *Cancer*, 122(23), 3715-3723.
83. Dahi, P. B., Morawa, E., Perales, M. A., **Zabor, E. C.**, Devlin, S. M., Maloy, M., Castro-Malaspina, H., O'Reilly, R. J., Papadopoulos, E. B., Jakubowski, A. A., & Giralt, S. A. (2016). Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS. *Bone Marrow Transplant*, 51(7), 991-993.
84. Bagrodia, A., Lee, B. H., Lee, W., Cha, E. K., Sfakianos, J. P., Iyer, G., Pietzak, E. J., Gao, S. P., **Zabor, E. C.**, Ostrovnaya, I., Kaffenberger, S. D., Syed, A., Arcila, M. E., Chaganti, R. S., Kundra, R., Eng, J., Hreiki, J., Vacic, V., Arora, K., Oschwald, D. M., Berger, M. F., Bajorin, D. F., Bains, M. S., Schultz, N., Reuter, V. E., Sheinfeld, J., Bosl, G. J., Al-Ahmadie, H. A., Solit, D. B., & Feldman, D. R. (2016). Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. *J Clin Oncol*, 34(33), 4000-4007.

85. Bagrodia, A., Cha, E. K., Sfakianos, J. P., **Zabor, E. C.**, Bochner, B. H., Al-Ahmadie, H. A., Solit, D. B., Coleman, J. A., Iyer, G., Scott, S. N., Shah, R., Ostrovnaya, I., Lee, B., Desai, N. B., Ren, Q., Rosenberg, J. E., Dalbagni, G., Bajorin, D. F., Reuter, V. E., & Coleman, J. A. (2016). Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. *J Urol*, 195(6), 1684-1689.
86. Albiges, L., Hakimi, A. A., Xie, W., McKay, R. R., Simantov, R., Lin, X., Lee, J. L., Rini, B. I., Srinivas, S., Bjarnason, G. A., Ernst, S., Wood, L. A., Vaishamayan, U. N., Rha, S. Y., Agarwal, N., Yuasa, T., Pal, S. K., Bamias, A., **Zabor, E. C.**, Skanderup, A. J., Furberg, H., Fay, A. P., de Velasco, G., Preston, M. A., Wilson, K. M., Cho, E., McDermott, D. F., Signoretti, S., Heng, D. Y. C., & Choueiri, T. K. (2016). Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. *J Clin Oncol*, 34(30), 3655-3663.
87. Al-Ahmadie, H. A., Iyer, G., Lee, B. H., Scott, S. N., Mehra, R., Bagrodia, A., Jordan, E. J., Gao, S. P., Ramirez, R., Cha, E. K., Desai, N. B., **Zabor, E. C.**, Ostrovnaya, I., Gopalan, A., Chen, Y. B., Fine, S. W., Tickoo, S. K., Gandhi, A., Hreiki, J., Viale, A., Arcila, M. E., Dalbagni, G., Rosenberg, J. E., Bochner, B. H., Bajorin, D. F., Berger, M. F., Reuter, V. E., Taylor, B. S., & Solit, D. B. (2016). Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. *Nat Genet*, 48(4), 356-358.
88. Sfakianos, J. P., Cha, E. K., Iyer, G., Scott, S. N., **Zabor, E. C.**, Shah, R. H., Ren, Q., Bagrodia, A., Kim, P. H., Hakimi, A. A., Ostrovnaya, I., Ramirez, R., Hanrahan, A. J., Desai, N. B., Sun, A., Pinciroli, P., Rosenberg, J. E., Dalbagni, G., Schultz, N., Bajorin, D. F., Reuter, V. E., Berger, M. F., Bochner, B. H., Al-Ahmadie, H. A., Solit, D. B., & Coleman, J. A. (2015). Genomic Characterization of Upper Tract Urothelial Carcinoma. *Eur Urol*, 68(6), 970-977.
89. Lubetkin, E. I., **Zabor, E. C.**, Isaac, K., Brennessel, D., Kemeny, M. M., Hay, J. L. (2015). Health literacy, information seeking, and trust in information in Haitians. *Am J Health Behav*, 39(3), 441-450.
90. Kim, P. H., Cha, E. K., Sfakianos, J. P., Iyer, G., **Zabor, E. C.**, Scott, S. N., Ostrovnaya, I., Ramirez, R., Sun, A., Shah, R., Yee, A. M., Reuter, V. E., Bajorin, D. F., Rosenberg, J. E., Schultz, N., Berger, M. F., Al-Ahmadie, H. A., Solit, D. B., & Bochner, B. H. (2015). Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. *Eur Urol*, 67(2), 198-201.
91. Bambury, R. M., Benjamin, D. J., Chaim, J. L., **Zabor, E. C.**, Sullivan, J., Garcia-Grossman, I. R., Regazzi, A. M., Ostrovnaya, I., Apollo, A., Xiao, H., Voss, M. H., Iyer, G., Bajorin, D. F., & Rosenberg, J. E. (2015). The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. *Oncologist*, 20(5), 508-515.
92. Sfakianos, J. P., Hakimi, A. A., Kim, P. H., **Zabor, E. C.**, Mano, R., Bernstein, M., Karellas, M., & Russo, P. (2014). Outcomes in patients undergoing nephrectomy for renal cancer on chronic anticoagulation therapy. *Eur J Surg Oncol*, 40(12), 1700-1705.
93. Mano, R., Hakimi, A. A., **Zabor, E. C.**, Bury, M. A., Donati, O. F., Karlo, C. A., Bazzi, W. M., Furberg, H., & Russo, P. (2014). Association between visceral and subcutaneous adiposity and clinicopathological outcomes in non-metastatic clear cell renal cell carcinoma. *Can Urol Assoc J*, 8(9-10), E675-680.
94. Lubetkin, E. I., **Zabor, E. C.**, Brennessel, D., Kemeny, M. M., Hay, J. L. (2014). Beyond demographics: differences in patient activation across new immigrant, diverse language subgroups. *J Community Health*, 39(1), 40-49.
95. Hayes, S. A., Soff, G. A., **Zabor, E. C.**, Moskowitz, C. S., Liu, C. C., Ginsberg, M. S. (2014). Clinical consequences of an indeterminate CT pulmonary angiogram in cancer

- patients. *Clin Imaging*, 38(5), 637-640.
96. Ehdaie, B., Furberg, H., **Zabor, E. C.**, Hakimi, A. A., Russo, P. (2014). Comprehensive assessment of the impact of cigarette smoking on survival of clear cell kidney cancer. *J Urol*, 191(3), 597-602.
 97. Do, R. K., Katz, S. S., Gollub, M. J., Li, J., LaFemina, J., **Zabor, E. C.**, Moskowitz, C. S., Klimstra, D. S., & Allen, P. J. (2014). Interobserver agreement for detection of malignant features of intraductal papillary mucinous neoplasms of the pancreas on MDCT. *AJR Am J Roentgenol*, 203(5), 973-979.
 98. **Zabor, E. C.**, Li, Y., Thornton, L. M., Shuman, M. R., Bulik, C. M., Lichtenstein, P., Pedersen, N. L., Sullivan, P. F., & Furberg, H. (2013). Initial reactions to tobacco use and risk of future regular use. *Nicotine Tob Res*, 15(2), 509-517.
 99. Weiss, M. J., Ito, H., Araujo, R. L., **Zabor, E. C.**, Gonen, M., D'Angelica, M. I., Allen, P. J., DeMatteo, R. P., Fong, Y., Blumgart, L. H., & Jarnagin, W. R. (2013). Hepatic pedicle clamping during hepatic resection for colorectal liver metastases: no impact on survival or hepatic recurrence. *Ann Surg Oncol*, 20(1), 285-294.
 100. Rink, M., **Zabor, E. C.**, Furberg, H., Xylinas, E., Ehdaie, B., Novara, G., Babjuk, M., Pycha, A., Lotan, Y., Trinh, Q. D., Chun, F. K., Lee, R. K., Karakiewicz, P. I., Fisch, M., Robinson, B. D., Scherr, D. S., & Shariat, S. F. (2013). Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. *Eur Urol*, 64(3), 456-464.
 101. Rink, M., Furberg, H., **Zabor, E. C.**, Xylinas, E., Babjuk, M., Pycha, A., Lotan, Y., Karakiewicz, P. I., Novara, G., Robinson, B. D., Montorsi, F., Chun, F. K., Scherr, D. S., & Shariat, S. F. (2013). Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. *Eur Urol*, 63(4), 724-732.
 102. Ridge, C. A., Huang, J., Cardoza, S., **Zabor, E. C.**, Moskowitz, C. S., Zakowski, M. F., & Ginsberg, M. S. (2013). Comparison of multiplanar reformatted CT lung tumor measurements to axial tumor measurement alone: impact on maximal tumor dimension and T stage. *AJR Am J Roentgenol*, 201(5), 959-963.
 103. Pannu, H. K., Ma, W., **Zabor, E. C.**, Moskowitz, C. S., Barakat, R. R., & Hricak, H. (2013). Enhancement of ovarian malignancy on clinical contrast enhanced MRI studies. *ISRN Obstet Gynecol*, 2013, 979345.
 104. McErlean, A., Panicek, D. M., **Zabor, E. C.**, Moskowitz, C. S., Bitar, R., Motzer, R. J., Hricak, H., & Ginsberg, M. S. (2013). Intra- and interobserver variability in CT measurements in oncology. *Radiology*, 269(2), 451-459.
 105. McErlean, A., Huang, J., **Zabor, E. C.**, Moskowitz, C. S., & Ginsberg, M. S. (2013). Distinguishing benign thymic lesions from early-stage thymic malignancies on computed tomography. *J Thorac Oncol*, 8(7), 967-973.
 106. Lefkowitz, R. A., Landa, J., Hwang, S., **Zabor, E. C.**, Moskowitz, C. S., Agaram, N. P., & Panicek, D. M. (2013). Myxofibrosarcoma: prevalence and diagnostic value of the "tail sign" on magnetic resonance imaging. *Skeletal Radiol*, 42(6), 809-818.
 107. Iyer, G., Al-Ahmadie, H., Schultz, N., Hanrahan, A. J., Ostrovnaya, I., Balar, A. V., Kim, P. H., Lin, O., Weinhold, N., Sander, C., **Zabor, E. C.**, Janakiraman, M., Garcia-Grossman, I. R., Heguy, A., Viale, A., Bochner, B. H., Reuter, V. E., Bajorin, D. F., Milowsky, M. I., Taylor, B. S., & Solit, D. B. (2013). Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. *J Clin Oncol*, 31(25), 3133-3140.
 108. Hakimi, A. A., Furberg, H., **Zabor, E. C.**, Jacobsen, A., Schultz, N., Ciriello, G., Mikkilineni, N., Fiegoli, B., Kim, P. H., Voss, M. H., Shen, H., Laird, P. W., Sander, C., Reuter, V. E., Motzer, R. J., Hsieh, J. J., & Russo, P. (2013). An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. *J Natl Cancer Inst*, 105(24), 1862-1870.

109. Ehdaie, B., Furberg, H., **Zabor, E. C.**, Ostroff, J. S., Shariat, S. F., Bochner, B. H., Coleman, J. A., & Dalbagni, G. (2013). Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. *BJU Int*, 111(4), 589-595.
110. Moskowitz, C. S., **Zabor, E. C.**, Jochelson, M. (2012). Breast imaging: understanding how accuracy is measured when lesions are the unit of analysis. *Breast J*, 18(6), 557-563.
111. Kadota, K., Suzuki, K., Kachala, S. S., **Zabor, E. C.**, Sima, C. S., Moreira, A. L., Yoshizawa, A., Riely, G. J., Rusch, V. W., Adusumilli, P. S., & Travis, W. D. (2012). A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. *Mod Pathol*, 25(8), 1117-1127.
112. Kadota, K., Colovos, C., Suzuki, K., Rizk, N. P., Dunphy, M. P., **Zabor, E. C.**, Sima, C. S., Yoshizawa, A., Travis, W. D., Rusch, V. W., & Adusumilli, P. S. (2012). FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. *Ann Surg Oncol*, 19(11), 3598-3605.
113. Abramson, D. H., Marr, B. P., Dunkel, I. J., Brodie, S., **Zabor, E. C.**, Driscoll, S. J., & Gobin, Y. P. (2012). Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. *Br J Ophthalmol*, 96(4), 499-502.
114. Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., **Zabor, E. C.**, Brogi, E., & Joyce, J. A. (2011). Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. *Genes Dev*, 25(23), 2465-2479.
115. Brader, P., Abramson, S. J., Price, A. P., Ishill, N. M., **Zabor, E. C.**, Moskowitz, C. S., La Quaglia, M. P., & Ginsberg, M. S. (2011). Do characteristics of pulmonary nodules on computed tomography in children with known osteosarcoma help distinguish whether the nodules are malignant or benign? *J Pediatr Surg*, 46(4), 729-735.
116. **Zabor, E. C.**, Klebanoff, M., Yu, K., Zhang, J., Nansel, T., Andrews, W., Schwebke, J., & Jeffcoat, M. (2010). Association between periodontal disease, bacterial vaginosis, and sexual risk behaviours. *J Clin Periodontol*, 37(10), 888-893.

Other publications

1. **Zabor, E. C.** (2021). Comment on "Age Conditional Probability of Ocular and Ocular Adnexal Malignancies". *Ocul Oncol Pathol*, 7(1), 74-75. doi:10.1159/000512031
2. Moo, T. A., Edelweiss, M., Hajiyeva, S., Stempel, M., Raiss, M., **Zabor, E. C.**, Barrio, A. V., & Morrow, M. (2020). Correction to: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? *Ann Surg Oncol*, 27(Suppl 3), 966. doi:10.1245/s10434-020-08273-4
3. **Zabor, E. C.** (2018). ASO Author Reflections: Careful Development and Thoughtful Interpretation are Needed when Developing Online Prognostic Tools. *Ann Surg Oncol*, 25(Suppl 3), 916-917.
4. Teo, M. Y., Bambury, R. M., **Zabor, E. C.**, Jordan, E., Al-Ahmadie, H., Boyd, M. E., Bouvier, N., Mullane, S. A., Cha, E. K., Roper, N., Ostrovnaya, I., Hyman, D. M., Bochner, B. H., Arcila, M. E., Solit, D. B., Berger, M. F., Bajorin, D. F., Bellmunt, J., Iyer, G., & Rosenberg, J. E. (2018). Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.". *Urol Oncol*, 36(7), 345-346.
5. Begg, C. B., Seshan, V. E., & **Zabor, E. C.** (2018). RE: "A MULTINOMIAL REGRESSION APPROACH TO MODEL OUTCOME HETEROGENEITY". *Am J Epidemiol*, 187(5), 1129-1130.
6. Moskowitz, C. S., **Zabor, E. C.**, Jochelson, M. (2013). Response to the "letter to the editor" by Dr. Thomas Filleron. *Breast J*, 19(2), 227.

R Packages

- **Emily C. Zabor**, Brian P. Hobbs and Michael J. Kane (2021). ppseq: Design Clinical Trials using Sequential Predictive Probability Monitoring. R package version 0.1.1. <https://cran.r-project.org/web/packages/ppseq/index.html>.
- Daniel D. Sjoberg, Margie Hannum, Karissa Whiting and **Emily C. Zabor** (2020). gtsummary: Presentation-Ready Data Summary and Analytic Result Tables. R package version 1.3.4. <https://CRAN.R-project.org/package=gtsummary>.
- **Emily C. Zabor**. riskclustr: Functions to Study Etiologic Heterogeneity. R package version 0.3. <https://cran.r-project.org/web/packages/riskclustr/>.
- condsurv: R package for conditional survival analysis, <https://github.com/zabore/condsurv>. *Note that this package is currently under development.*
- ezfun: R package to generate tables for clinical projects for use in word R Markdown files, <https://github.com/zabore/ezfun>. *Note that this package is primarily for personal use.*

R Tutorials

- “Survival Analysis in R.” Memorial Sloan Kettering Cancer Center Department of Strategy & Innovation R Presenter Series. August 30, 2018. Materials available online at http://www.emilyzabor.com/tutorials/survival_analysis_in_r_tutorial.html
- “Creating Websites in R.” Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics R User Group. January 23, 2018. Re-presented at the R-Ladies NYC Meetup on February 15, 2018. Materials available online at http://www.emilyzabor.com/tutorials/rmarkdown_websites_tutorial.html
- “Demonstration of utility functions for R Markdown reports in Word.” Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics R User Group. December 6, 2016.
- “Longitudinal data analysis.” Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics Masters Seminar Series. July 28, 2015.
- “Conditional survival.” Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics Masters Seminar Series. November 13, 2012.
- “Binary recursive partitioning with rpart and rpart.plot.” Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics Masters Seminar Series. August 23, 2011.

Presentations

Invited

- “Brief Introduction to Phase II Designs in Oncology.” Seventh International Conference on Statistics for Twenty-first Century (virtual), December 15, 2021.
- “Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level for Precision Oncology.” Joint Statistical Meetings (virtual), August 10, 2021.
- “Reporting Effect Size and Precision in Clinical Research.” American Urological Association Methods in Clinical Urology Research (MCUR) Workshop (virtual), July 26, 2021.
- “Bayesian basket trial design with false discovery rate control.” International Indian Statistical Association Conference (virtual), May 20, 2021.

- “Creating presentation-ready summary tables with gtsummary.” Greater Cleveland R User Group, Cleveland, OH (virtual), September 30, 2020.
- “Etiologic heterogeneity in cancer.” Cleveland Clinic Florida Cancer Grand Rounds, Weston, FL, January 3, 2020.
- “Statistical methods for the study of etiologic heterogeneity.” Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY, December 10, 2018.
- “Statistical methods for the study of etiologic heterogeneity.” Cleveland Clinic Department of Quantitative Health Sciences, Cleveland, OH, November 16, 2018.
- “Statistical methods for the study of etiologic heterogeneity.” NYU School of Medicine Department of Population Health, Division of Biostatistics, New York, NY, October 30, 2018.
- “Validity of a method for identifying etiologically heterogeneous disease subtypes.” Mayo Clinic Department of Health Sciences Research, Rochester, MN, September 25, 2018.
- “Teaching survival analysis to clinical collaborators.” R/Medicine Conference, New Haven, CT, September 7, 2018.
- “How long will I live? The statistics behind prognosis in cancer research.” New York R Conference, New York, NY, April 21, 2018.

Contributed

- “Designing early phase clinical trials with {ppseq}.” R/Medicine Conference (virtual), August 27, 2021.
- “Validity of a method for identifying disease subtypes that are etiologically heterogeneous.” Joint oral and poster presentation at the Joint Statistical Meetings, Vancouver, BC, Canada, July 31, 2018.
- “Validity of a method for identifying disease subtypes that are etiologically heterogeneous.” Eastern North American Region of the International Biometric Society, Atlanta, GA, March 27, 2018.
- “Dimension reduction in the study of etiologic heterogeneity, Oral presentation.” Joint Statistical Meetings, Baltimore, MD, August 1, 2017.
- “A comparison of statistical methods for the study of etiologic heterogeneity.” Poster presentation at the Society for Epidemiologic Research, Seattle, WA, June 20, 2017.
- “A comparison of statistical methods for the study of etiologic heterogeneity.” Poster presentation at the Eastern North American Region of the International Biometric Society, Washington DC, March 12, 2017.
- “A review of statistical methods for evaluating etiologic heterogeneity.” Third International Molecular Pathologic Epidemiology Meeting, Boston, MA, May 12, 2016.
- “Initial reactions to tobacco and risk of future regular tobacco use.” Poster presentation at the Third North American Congress of Epidemiology, Montreal, QC, Canada, June 23, 2011.
- “Association between periodontal disease, bacterial vaginosis, and sexual risk behaviours.” Oral presentation at the American Association for Dental Research Meetings, Washington DC, March 5, 2010.

Service and memberships

Intramural service

- 2021 Guest lecturer, "Introduction to R and RStudio", Cleveland Clinic Lerner College of Medicine Molecular Medicine PhD Tools course.
- 2021 Co-Instructor, Biostatistics and Epidemiology, Cleveland Clinic Lerner College of Medicine Molecular Medicine PhD program.
- 2020-2021 Statistical Mentor, Taussig Cancer Institute Fellows Journal Club.
- 2020 Clinical Abstract Review Committee, CCF Research Day.
- 2020 Faculty Assessor, Cleveland Clinic Lerner College of Medicine Clinical Research Block Presentations.
- 2020 Search Committee, LRI Staff Biostatistician
- 2019 Statistician Contributor, 2nd Annual Advances in Early Lung Cancer Detection Conference Breakout Sessions, Cleveland Clinic.
- 2019 Faculty Assessor, Cleveland Clinic Lerner College of Medicine Clinical Research Block Presentations.
- 2018–2019 Founder and Chair, Memorial Sloan Kettering Department of Epidemiology & Biostatistics Coding Workshop. Introduced a monthly workshop with the goal of learning best practices for coding style and efficiency, through peer-review of code.
- 2016–2019 Member, Memorial Sloan Kettering Department of Epidemiology & Biostatistics R User Group

Extramural service

- 2021–present Chief Statistician, Journal of Urology.
- 2021 Session chair, "Variable selection and its application in biomedical sciences" International Indian Statistical Association Conference, Virtual.
- 2020 Session chair, "Trial Design with Subpopulation Heterogeneity: What Is the Role of Real-World Evidence?" Joint Statistical Meetings, Virtual.
- 2020–Present Associate Editor, R Journal.
- 2019–Present Member, Council on Emerging and New Statisticians, Eastern North American Region of the International Biometric Society
- 2019–Present Editorial Board, European Urology
- 2018–2020 Editorial Board of Statisticians, Journal of Urology.
- 2018–Present *Ad hoc* reviewer, Journal of the American Statistical Association
- 2017–Present *Ad hoc* reviewer, Journal of Clinical Oncology
- 2016–2019 Board member, R-Ladies NYC.
- 2013–2017 *Ad hoc* statistical reviewer, Journal of Urology

Memberships

- 2017–2020 Society for Epidemiologic Research, Member
- 2015–2020 American Society of Clinical Oncology, Member
- 2011–Present Eastern North American Region of the International Biometric Society, Member
- 2010–Present American Statistical Association, Member

Honors and awards

- 2017 Travel Awardee, American Statistical Association Section on Statistics in Epidemiology
- 2009 Outstanding Teaching Assistant Award, The University of Minnesota
- 2003 Ralph A. Leubben Prize for Anthropology, Grinnell College
- 2002-2003 Mortar Board Honor Society, Grinnell College